RARE DISEASERESEARCH ATLAS

ORPHA:455

Superficial epidermolytic ichthyosis

medium confidenceDisorder

Also known as: Ichthyosis bullosa of Siemens · SEI

Publications

165

55.8th percentile

Trials

0

Interventional, condition-specific

Researchers

810

Distinct authors in sample

Gene link

KRT2

Definitive

Readiness

2/6

Stages with a signal

Clinical definition (Orphanet)

Superficial epidermolytic ichthyosis (SEI) is a rare keratinopathic ichthyosis (KI) characterized by the presence of superficial blisters and erosions at birth.

How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (2)

ichthyosis bullosa of Siemens · superficial epidermolytic ichthyosis

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

2/6 stages with a signal

No matched interventional trial; the gene is known and literature exists — preclinical or natural-history work may still be the practical next step.

  1. Gene identifiedPresent

    Definitive — KRT2

  2. LiteraturePresent

    165 matched papers (57 in last 10 years) Source

  3. Phenotype characterisedNot checked

    Not yet enriched from Monarch / HPO

  4. Animal modelNot checked

    Not yet enriched from Monarch / Alliance

  5. Orphan designationNot checked

    FDA/EMA orphan-drug designation not enriched yet

  6. Interventional trialNot found

    No matched interventional trial under our ClinicalTrials.gov rules

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Yes — we know a specific gene responsible (KRT2).

GenCC classification: Definitive.

Phenotypes (Monarch / HPO)

Not enriched in this build — Monarch phenotype joins were not run for this record.

Animal models (Monarch / Alliance)

Not enriched in this build.

Literature

Is anyone studying this?

165

165 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.

165 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).

57 in the last 10 years · medium confidence · 55.8th percentile (publications denominator)

Phrase hits: 165 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

810

Distinct author names in 165 sampled papers — named people below.

Who's working on it?

No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.

  1. 01
    McLean WH10 papers · 2007

    Human Genetics Unit, University of Dundee, Dundee, UK

    Papers in Europe PMC
  2. 02
    Akiyama M9 papers · 2022

    Department of Dermatology, Nagoya University Graduate School of Medicine, Japan. makiyama@med.nagoya-u.ac.jp

    Papers in Europe PMC
  3. 03
    Fischer J9 papers · 2026

    Institute of Human Genetics, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, 79106 Freiburg, Germany. Electronic address: judith.fischer@uniklinik-freiburg.de.

    Papers in Europe PMC
  4. 04
    Traupe H7 papers · 2026

    Department of Dermatology, University Hospital of Münster, Münster, Germany.

    Papers in Europe PMC
  5. 05
    Oji V6 papers · 2026

    Department of Dermatology, University Hospital Münster, Münster, Germany. ojiv@uni-muenster.de

    Papers in Europe PMC
  6. 06
    Leigh IM5 papers · 2004
    Papers in Europe PMC
  7. 07
    Schmuth M5 papers · 2026

    Department of Dermatology, University of California, VAMC Metabolism 111F, 4150 Clement Street, San Francisco, CA 94121, USA. schmuthm@derm.ucsf.edu

    Papers in Europe PMC
  8. 08
    Shimizu H5 papers · 2010
    Papers in Europe PMC
  9. 09
    Eady RA4 papers · 2001
    Papers in Europe PMC
  10. 10
    Happle R4 papers · 1994
    Papers in Europe PMC

Clinical research

Is a treatment being tested?

0

interventional trials for this specific condition

No interventional trial testing a treatment matched this specific condition name. 1 observational study did — shown below because natural-history and cohort work can be an important step toward a trial.

Data as of 27 July 2026

No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.

medium confidence · 36.5th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.

See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.

Observational and natural-history studies

1 observational study matches this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.

None of the matched observational studies is currently listed as recruiting.

Open the complete matched search on ClinicalTrials.gov

Where to find support

We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Superficial epidermolytic ichthyosis" OR "Ichthyosis bullosa of Siemens" OR "Ichthyosis bullosa of the Siemens"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Superficial epidermolytic ichthyosis" OR "Ichthyosis bullosa of Siemens" OR "Ichthyosis bullosa of the Siemens" OR "KRT2" OR "keratinopathic ichthyosis" OR "exfoliative ichthyosis" OR "inherited ichthyosis"

Recall-expansion terms: KRT2, keratinopathic ichthyosis, exfoliative ichthyosis, inherited ichthyosis

Study-type breakdown: 0 interventional · 1 observational · 0 expanded access. Only interventional studies enter the trial headline.

Query health: ok — strategies attempted: phrase, recall-expansion; with hits: phrase, recall-expansion

Run this search on ClinicalTrials.gov

Synonyms dropped by stoplist: SEI

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • 1 synonym(s) dropped by stoplist (may under-count)
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-26T13:53:57.336Z